CO2021000817A2 - Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 - Google Patents
Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1Info
- Publication number
- CO2021000817A2 CO2021000817A2 CONC2021/0000817A CO2021000817A CO2021000817A2 CO 2021000817 A2 CO2021000817 A2 CO 2021000817A2 CO 2021000817 A CO2021000817 A CO 2021000817A CO 2021000817 A2 CO2021000817 A2 CO 2021000817A2
- Authority
- CO
- Colombia
- Prior art keywords
- interleukin
- inhibitors
- activity
- sulfonylurea compounds
- nlrp3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación se refiere a nuevos compuestos de sulfonilurea y compuestos relacionados útiles en el tratamiento de un trastorno sensible a la modulación de citocinas tales como IL-1β e IL-18, modulación de NLRP3 o inhibición de la activación de NLRP3 o componentes relacionados del proceso inflamatorio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701358P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042703 WO2020018970A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021000817A2 true CO2021000817A2 (es) | 2021-02-17 |
Family
ID=67515207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0000817A CO2021000817A2 (es) | 2018-07-20 | 2021-01-26 | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11560391B2 (es) |
| EP (1) | EP3823726A1 (es) |
| JP (1) | JP7411631B2 (es) |
| KR (1) | KR20210034588A (es) |
| CN (1) | CN112437683A (es) |
| AR (1) | AR117617A1 (es) |
| AU (1) | AU2019305095A1 (es) |
| BR (1) | BR112021001012A2 (es) |
| CA (1) | CA3104199A1 (es) |
| CL (1) | CL2021000152A1 (es) |
| CO (1) | CO2021000817A2 (es) |
| CR (1) | CR20210024A (es) |
| IL (1) | IL280139A (es) |
| MA (1) | MA53170A (es) |
| MX (1) | MX2021000660A (es) |
| PE (1) | PE20211049A1 (es) |
| PH (1) | PH12020552155A1 (es) |
| SG (1) | SG11202012159TA (es) |
| TW (1) | TW202019937A (es) |
| WO (1) | WO2020018970A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20190356A (es) | 2017-01-23 | 2019-11-20 | Genentech Inc | Compuestos químicos como inhibidores de la actividad de la interleuquina-1 |
| CN111093773A (zh) | 2017-08-15 | 2020-05-01 | 英夫拉索姆有限公司 | 作为nlrp3抑制剂的磺酰脲和磺酰硫脲 |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| RU2020115098A (ru) | 2017-11-09 | 2021-12-10 | Инфлазоум Лимитед | Соединения новых сульфонамидкарбоксамидов |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US20220378801A1 (en) | 2019-06-21 | 2022-12-01 | Ac Immune Sa | Novel compounds |
| BR112022009209A2 (pt) * | 2019-11-12 | 2022-07-26 | Chengdu Baiyu Pharmaceutical Co Ltd | Derivado de amida e método de preparação e uso do mesmo na medicina |
| MX2022014709A (es) | 2020-06-19 | 2022-12-16 | Ac Immune Sa | Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3). |
| WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| WO2023158824A1 (en) * | 2022-02-21 | 2023-08-24 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin- 1 activity |
| US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| ES2198598T3 (es) | 1997-01-29 | 2004-02-01 | Pfizer Inc. | Derivados de sulfonilurea y su uso en el control de la actividad de la interleuquina-1. |
| AU6464400A (en) | 1999-09-14 | 2001-04-17 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| WO2003045400A1 (en) | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| CN102770159A (zh) * | 2010-02-22 | 2012-11-07 | 拉夸里亚创药株式会社 | Ep-4受体拮抗剂在治疗il-23介导疾病中的用途 |
| WO2013031931A1 (ja) | 2011-09-02 | 2013-03-07 | 協和発酵キリン株式会社 | ケモカイン受容体活性調節剤 |
| EP3888749A1 (en) * | 2015-02-16 | 2021-10-06 | The University of Queensland | Sulfonylureas and related compounds and use of same |
| MA44225A (fr) | 2016-02-16 | 2018-12-26 | The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv | Sulfonylurées et composés apparentés et leur utilisation |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| AU2017254522B2 (en) | 2016-04-18 | 2021-09-23 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| CR20190356A (es) * | 2017-01-23 | 2019-11-20 | Genentech Inc | Compuestos químicos como inhibidores de la actividad de la interleuquina-1 |
| WO2018215818A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| WO2019008029A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| PL3661925T3 (pl) | 2017-07-07 | 2022-02-28 | Inflazome Limited | Nowe związki sulfonamidowo karboksyamidowe |
| JP2020531448A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| CN111093773A (zh) | 2017-08-15 | 2020-05-01 | 英夫拉索姆有限公司 | 作为nlrp3抑制剂的磺酰脲和磺酰硫脲 |
| WO2019034688A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| TW201910314A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| RU2020115098A (ru) | 2017-11-09 | 2021-12-10 | Инфлазоум Лимитед | Соединения новых сульфонамидкарбоксамидов |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US20200354341A1 (en) | 2017-11-09 | 2020-11-12 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| WO2020010118A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
| EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| AU2019306658A1 (en) | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| AU2019322546A1 (en) | 2018-08-15 | 2021-03-04 | Inflazome Limited | Novel sulfonamideurea compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| WO2020086732A1 (en) | 2018-10-24 | 2020-04-30 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020154321A1 (en) | 2019-01-22 | 2020-07-30 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
-
2019
- 2019-07-19 CN CN201980048411.9A patent/CN112437683A/zh active Pending
- 2019-07-19 WO PCT/US2019/042703 patent/WO2020018970A1/en unknown
- 2019-07-19 PE PE2021000074A patent/PE20211049A1/es unknown
- 2019-07-19 CA CA3104199A patent/CA3104199A1/en active Pending
- 2019-07-19 JP JP2021502998A patent/JP7411631B2/ja active Active
- 2019-07-19 SG SG11202012159TA patent/SG11202012159TA/en unknown
- 2019-07-19 AU AU2019305095A patent/AU2019305095A1/en not_active Abandoned
- 2019-07-19 EP EP19749134.3A patent/EP3823726A1/en active Pending
- 2019-07-19 KR KR1020217001676A patent/KR20210034588A/ko unknown
- 2019-07-19 BR BR112021001012-2A patent/BR112021001012A2/pt not_active Application Discontinuation
- 2019-07-19 CR CR20210024A patent/CR20210024A/es unknown
- 2019-07-19 MA MA053170A patent/MA53170A/fr unknown
- 2019-07-19 MX MX2021000660A patent/MX2021000660A/es unknown
- 2019-07-22 TW TW108125890A patent/TW202019937A/zh unknown
- 2019-07-22 AR ARP190102054A patent/AR117617A1/es unknown
-
2020
- 2020-12-14 PH PH12020552155A patent/PH12020552155A1/en unknown
-
2021
- 2021-01-12 IL IL280139A patent/IL280139A/en unknown
- 2021-01-15 US US17/150,380 patent/US11560391B2/en active Active
- 2021-01-19 CL CL2021000152A patent/CL2021000152A1/es unknown
- 2021-01-26 CO CONC2021/0000817A patent/CO2021000817A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA53170A (fr) | 2021-05-26 |
| EP3823726A1 (en) | 2021-05-26 |
| CN112437683A (zh) | 2021-03-02 |
| JP7411631B2 (ja) | 2024-01-11 |
| KR20210034588A (ko) | 2021-03-30 |
| JP2021530536A (ja) | 2021-11-11 |
| AU2019305095A1 (en) | 2020-12-17 |
| CL2021000152A1 (es) | 2021-07-09 |
| BR112021001012A2 (pt) | 2021-04-20 |
| CA3104199A1 (en) | 2020-01-23 |
| SG11202012159TA (en) | 2021-01-28 |
| MX2021000660A (es) | 2021-03-25 |
| US11560391B2 (en) | 2023-01-24 |
| AR117617A1 (es) | 2021-08-18 |
| WO2020018970A1 (en) | 2020-01-23 |
| US20210261568A1 (en) | 2021-08-26 |
| PH12020552155A1 (en) | 2021-07-05 |
| CR20210024A (es) | 2021-02-22 |
| IL280139A (en) | 2021-03-01 |
| TW202019937A (zh) | 2020-06-01 |
| PE20211049A1 (es) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021000817A2 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 | |
| CO2021001530A2 (es) | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 | |
| CO2019009036A2 (es) | Compuestos químicos como inhibidores de la actividad de la interleuquina-1 | |
| CL2019001709A1 (es) | Derivados pirazol como inhibidores de malt1. | |
| CO2017006997A2 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| CO2020002588A2 (es) | Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer | |
| CL2019000511A1 (es) | Inhibidores de procesos metabólicos celulares. | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| MA40076A (fr) | Inhibiteurs de syk | |
| PE20160200A1 (es) | Inhibidores de bromodominios | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CL2020003083A1 (es) | Inhibidores de masp-2 y métodos de uso | |
| MX2019001376A (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados. | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| CU20200041A7 (es) | Amidas de imidazopiridina sustituidas | |
| CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
| UY34615A (es) | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| CL2019001397A1 (es) | Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa. | |
| TN2017000465A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| AR113514A1 (es) | Composiciones y métodos para mejorar la utilización del fósforo y el calcio en la dieta de los animales |